According to reports in the local media, the new plant in Arklow, County Wicklow, is the final stage of a €124m investment and infrastructure development programme.
ENN reported that the 4,500 sqm facility will act as a centre for the company's R&D activities and has created 100 new drug development and manufacturing jobs.
In December, a Business Insights report suggested that Servier, along with fellow specialist pharma firms Shire, Biogen, Cephalon and Sepracor would turn to internal R&D rather than the traditional in-licensing approach to drive revenues.
Servier’s new facility lends further support to this idea. However, given the tumult of the last 12 months, whether the firm will continue to pursue this strategy as vigorously as it would have last year remains to be seen.